Prescribing antipsychotics for children and adolescents

Advances in Psychiatric Treatment

Volumn 16, Issue 1, 2010, Pages 63-75

  James, Anthony C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BENZATROPINE; CHLORPROMAZINE; CLONIDINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ADOLESCENT; AKATHISIA; ANOREXIA NERVOSA; ANTICHOLINERGIC EFFECT; APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; CHILD; CLINICAL TRIAL; COGNITION; CONDUCT DISORDER; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DISRUPTIVE BEHAVIOR; DIZZINESS; DROWSINESS; DYSKINESIA; DYSLIPIDEMIA; EFFECT SIZE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FATIGUE; GASTROINTESTINAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPOKINESIA; MUSCLE HYPERTONIA; NEUTROPENIA; OBSESSIVE COMPULSIVE DISORDER; PARKINSONISM; PRESCRIPTION; PSYCHOSOCIAL CARE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TIC; TREMOR; WAKEFULNESS; WEIGHT GAIN; WITHDRAWAL DYSKINESIA;

EID: 77949509366     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.bp.108.005652     Document Type: Article

References (90)

1. Agrid O, Remington G, Kapur S, et al (2007) Early use of clozapine for poorly responding first-episode psychosis. Journal of Clinical Psychopharmacology; 27: 369-73.
2. Álvarez-Jiménez M, Hetrick SE, González-Blanch C, et al (2008) Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. British Journal of Psychiatry; 193: 101-7.
3. Aman M, De Smedt G, Derivan A, et al (2002) Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. American Journal of Psychiatry; 159: 1337-46.
4. Armenteros J, Davies M (2006) Antipsychotics in early-onset schizophrenia. Systematic review and meta-analysis. European Journal of Child and Adolescent Psychiatry; 15: 141-8.
5. Bachmann C, Haberhausen M, Heizel-Gutenbrunner M, et al (2008) Large intraindividual variability of olanzapine serum concentrations in adolescent patients. Therapeutic Drug Monitoring; 30: 108-12.
6. Berger G, Proffitt T, McConchie M, et al (2008) Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumurate in 141 patients aged 15 to 25 years. Journal of Clinical Psychiatry; 69: 1702-14.
7. Bigos K, Pollock B, Coley K, et al (2008) Sex, race, and smoking impact olanzapine exposure. Journal of Clinical Pharmacology; 48: 157-65.
8. Blair J, Scahill L, State M, et al (2005) Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. Journal of the American Academy of Child and Adolescent Psychiatry; 44: 73-9.
9. Bloch M, Landeros-Weisenberger A, Kelmendi B, et al (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry; 11: 622-32.
10. Buckley P, Correll C (2008) Strategies for dosing and switching for optimal clinical management. Journal of Clinical Psychiatry; 69 (suppl 1): 4-17.
11. Buitelaar JK, van der Gaag, Cohen-Kettenis P, et al (2001) A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Journal of Clinical Psychiatry; 62: 239-48.
12. Campbell M, Small A, Green W, et al (1984) Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Archives of General Psychiatry; 41: 650-6.
13. Chavez B, Chavez-Brown M, Sopko Jr M, et al (2007) Atypical antipsychotics in children with pervasive developmental disorders. Paediatric Drugs; 9: 249-66.
14. Correll C, Carlson H (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry; 45: 771-91.
15. Correll C, Kane J (2007) One-year tardive dyskinesia rates in children and adolescents treated with second-generation antipsychotics: a systematic review. Journal of Child and Adolescent Psychopharmacology; 17: 647-55.
16. Correll C (2008) Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. Journal of the American Academy of Child and Adolescent Psychiatry; 47: 9-20.
17. DelBello M, Schwiers M, Rosenberg H, et al (2002) A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. Journal of the American Academy of Child and Adolescent Psychiatry; 41: 1216-23.
18. DelBello M, Kowatch R, Adler C, et al (2006) A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. Journal of the American Academy of Child and Adolescent Psychiatry; 45: 305-13.
19. Doey T, Handelman K, Seabrook J, et al (2007) Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental paediatricians for patients aged under 18 years. Canadian Journal of Psychiatry; 52: 363-8.
20. Engelhardt D, Polizos P, Waizer J, et al (1973) A double blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children. Journal of Autism and Childhood Schizophrenia; 3: 128-37.
21. Faretra G, Dooher L, Dowling J (1970) Comparison of haloperidol and fluphenazine in disturbed children. American Journal of Psychiatry; 126: 1670-3.
22. Findling R, McNamara N, Branicky L, et al (2000) A double-blind pilot study of risperidone in the treatment of conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry; 39: 509-16.
23. Findling RL, Kusumakar V, Daneman D, et al (2003) Prolactin levels during long-term risperidone treatment in children and adolescents. Journal of Clinical Psychiatry; 64: 1362-9.
24. Findling RL, Steiner H, Weller EB (2005) Use of antipsychotics in children and adolescents. Journal of Clinical Psychiatry; 66: 29-40.
25. Findling R, Frazier J, Gerbino-Rosen G, et al (2007) Is there a role for clozapine in the treatment of children and adolescents? Journal of the American Academy of Child and Adolescent Psychiatry; 46: 423-8.
26. Findling R, Kauffman R, Sallee F, et al (2008) Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose escalation study. Journal of Clinical Psychopharmacology; 28: 441-6.
27. Gaffney G, Perry P, Lund B, et al (2002) Risperidone versus clonidine in the treatment of children and adolescents with Tourette's Syndrome. Journal of the American Academy of Child and Adolescent Psychiatry; 41: 330-6.
28. Gerbino-Rosen G, Roofeh D, Tompkins D, et al (2005) Hematological adverse events in clozapine-treated children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry; 44: 1024-31.
29. Gilbert D, Batterson J, Sethuraman G, et al (2004) Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. Journal of the American Academy of Child and Adolescent Psychiatry; 43: 206-14.
30. Gleason M, Egger H, Emslie G, et al (2007) Psychopharmacological treatment for very young children: contexts and guidelines. Journal of the American Academy of Child and Adolescent Psychiatry; 46: 1532-72.
31. Gogtay N, Rapoport J (2008) Clozapine use in children and adolescents. Expert Opinion on Pharmacotherapy; 9: 459-65.
32. Goldberg T, Goldman R, Burdick K, et al (2007) Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Archives of General Psychiatry; 64: 1115-22.
33. Goodyer I, Dubicka B, Wilkinson P, et al (2007) Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ; 335: 142.
34. Haas M, DelBello MP, Pandina G, et al (2009a) Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disorders; 11: 687-700.
35. Haas M, Eerdekens M, Kushner S, et al (2009b) Efficacy, safety and tolerability of two dosing regimes in adolescent schizophrenia: a double-blind study. British Journal of Psychiatry; 194: 158-64.
36. Harrison-Woolrych M, Garcia-Quiroga J, Ashton J, et al (2007) Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Safety; 30: 569-79.
37. Hobbs J, Peterson D, Moss A (2006) Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-OT syndrome. JAMA; 296: 1249-54.
38. Hollander E, Wasserman S, Swanson E, et al (2006) A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology; 16: 541-8.
39. Jensen S, Buitelaar J, Pandina G, et al (2007) Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. European Child and Adolescent Psychiatry; 16: 104-20.
40. Kafantaris V, Coletti D, Dicker R, et al (2001) Adjunctive antipsychotic treatment of adolescents with bipolar psychosis. Journal of the American Academy of Child and Adolescent Psychiatry; 40: 1448-56.
41. Kapur S, Zipursky R, Jones C, et al (2000) Relationship between dopamine D(2) occupancy, clinical response, and side-effects: a double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry; 157: 154-20.
42. Kapur S (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry; 160: 13-23.
43. Kennedy E, Kumar A, Datta SS (2007) Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database of Systematic Reviews; issue 3: CD004027.
44. Klein D, Cottingham E, Sorter M, et al (2006) A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. American Journal of Psychiatry; 163: 2072-9.
45. Kowatch RA, Fristad M, Birmaher B, et al (2005) Treatment guidelines for children and adolescents with bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry; 44: 213-35.
46. Kryzhanovskaya L, Schulz S, McDougle C, et al (2009) Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry; 48: 60-70.
47. Kumra S, Frazier J, Jacobsen L, et al (1996) Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Archives of General Psychiatry; 53: 1090-7.
48. Kumra S, Kranzler H, Gerbino-Rosen G, et al (2008) Clozapine and 'high-dose' olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biological Psychiatry; 63: 524-9.
49. Leucht S, Komossa K, Rummel-Kluge C, et al (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry; 166: 152-63.
50. Lewis S, Lieberman J (2008) CATIE and CUtLASS: can we handle the truth? British Journal of Psychiatry; 192: 161-3.
51. Luby J, Mrakotsky C, Stalets MM, et al (2006) Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. Journal of Child and Adolescent Psychopharmacology; 16: 575-87.
52. March J, Silva S, Petrycki S, et al (2004) Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA; 292: 807-20.
53. McCracken J, McGough J, Shah B, et al (2002) Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine; 347: 314-21.
54. McDougle C, Scahill L, Aman MG, et al (2005) Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry; 162: 1142-8.
55. Medicines and Healthcare products Regulatory Agency (2007) Medicine for children. MHRA (http://www.mhra.gov.uk/Howweregulate/Medicines/ Medicinesforchildren/index.htm).
56. Mehler-Wex C, Romanos M, Kirhheimer J, et al (2008) Atypical antipsychotics in severe anorexia nervosa in children and adolescents - review and case reports. European Eating Disorders Review; 16: 100-8.
57. Miral S, Gencer O, Inal-Emiroglu F, et al (2008) Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. European Child and Adolescent Psychiatry; 17: 1-8.
58. Morgan S, Taylor E (2007) Antipsychotic drugs in children with autism. BMJ; 334: 1069-70.
59. Mukundan A, Faulkner G, Cohn T, et al (2007) Antipsychotic switching for people with schizophrenia who have neuroleptics induced weight or metabolic problems (Protocol). Cochrane Database of Systematic Reviews; issue 3: CD006629.
60. Nagaraj R, Singhi P, Malhi P (2006) Risperidone in children with autism: randomized, placebo-controlled, double-blind study. Journal of Child Neurology; 21: 450-5.
61. National Collaborating Centre for Mental Health (2002) Schizophrenia - Atypical Antipsychotics. National Institute for Health and Clinical Excellence (http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11460).
62. National Collaborating Centre for Mental Health (2004) Eating Disorders: Core Interventions in the Treatment of Anorexia Nervosa, Bulimia Nervosa, and Related Eating Disorders. National Institute for Health and Clinical Excellence (http://www.nice.org.uk/nicemedia/pdf/cg009niceguidance.pdf) .
63. National Institute for Health and Clinical Excellence (2005) Latest NICE guidance sets new standards for treating depression in children and young people. NICE (http://www.nice.org.uk/guidance/index. jsp?action=download&o= 29862).
64. National Institute for Health and Clinical Excellence (2006) Conduct disorders in children - new guidance to help parents. NICE (http:// www.nice.org.uk/newsroom/guidanceinfocus/conduct-disorders-in- children--new-guidance-to-help-parents.jsp).
65. Olfson M, Blanco C, Liu L, et al (2006) National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry; 63: 679-85.
66. Pediatric OCD Treatment Study (POTS) Team (2004) Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA; 292: 1969-76.
67. Pool D, Bloom W, Mielke D, et al (1976) A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Current Therapeutic Research, Clinical and Experimental; 19: 99-104.
68. Realmuto G, Erickson W, Yellin A, et al (1984) Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. American Journal of Psychiatry; 141: 440-2.
69. Reyes M, Buitelaar J, Toren P, et al (2006) A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. American Journal of Psychiatry; 163: 402-10.
70. Sallee F, Nesbitt L, Jackson C, et al (1997) Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. American Journal of Psychiatry; 154: 1057-62.
71. Sallee F, Kurlan R, Goetz C, et al (2000) Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. Journal of the American Academy of Child and Adolescent Psychiatry; 39: 292-9.
72. Sanford M, Keating G (2007) Aripiprazole in adolescents with schizophrenia. Paediatric Drugs; 9: 419-23.
73. Scahill L, Leckman J, Schultz R, et al (2003) A placebo-controlled trial of risperidone in Tourette syndrome. Neurology; 60: 1130-5.
74. Shaw P, Sporn A, Gogtay N, et al (2006) Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Archives of General Psychiatry; 63: 721-30.
75. Shea S, Turgay A, Carroll A, et al (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics; 114: e634-41.
76. Shelton R, Papakostas G (2008) Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatrica Scandinavica; 117: 253-9.
77. Sikich L, Hamer R, Bashford R, et al (2004) A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology; 29: 133-45.
78. Sikich L, Frazier J, McClellan J, et al (2008) Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. American Journal of Psychiatry; 165: 1420-31.
79. Snyder R, Turgay A, Aman M, et al (2002) Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. Journal of the American Academy of Child and Adolescent Psychiatry; 41: 1026-36.
80. Spencer E, Kafantaris V, Padron-Gayol M, et al (1992) Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacology Bulletin; 28: 183-6.
81. Sporn A, Vermani A, Greenstein D, (2007) Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. Journal of the American Academy of Child and Adolescent Psychiatry; 46: 1349-56.
82. Spettigue W, Buchholz A, Henderson K, et al (2008) Evaluation of the efficacy and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescent females: a randomized, double-blind, placebo-controlled trial. BMC Pediatrics; 8: 4.
83. Sporn A, Gogtay N, Ortiz-Aguavo R, et al (2003) Clozapine-induced neutropenia in children: management with lithium carbonate. Journal of Child and Adolescent Psychopharmacology; 13: 401-4.
84. Tohen M, Kryzhanovskaya L, Carlson G, et al (2007) Olanzapine versus placebo in the treatment of adolescents with bipolar mania. American Journal of Psychiatry; 164: 1547-56.
85. Troost P, Lahuis B, Steenhuis MP, et al (2005) Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry; 44: 1137-44.
86. Van Bellighen M, De Troch C (2001) Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. Journal of Child and Adolescent Psychopharmacology; 11: 5-13.
87. Watson J, Rees C (2008) Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder. Journal of Child Psychology and Psychiatry; 49: 489-98.
88. Wu RR, Zhao JP, Guo XF, et al (2008) Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry; 165: 352-8.
89. Xiong Y (2004) Comparison study of childhood schizophrenia treated with risperidone and chlorpromazine. Guizhou Medical Journal; 28: 697-8.
90. Yao H (2003) A study of risperidone in the treatment of child schizophrenia. Journal of Clinical Psychological Medicine; 7468: 801.